文献速递乳腺癌妇科肿瘤

低中收入与高收入国家当代肿瘤随机临床试验分析

An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries.
PubMed 文献 · JAMA Oncol · 2021-01-01

该回顾性队列研究分析了2014至2017年发表的694项抗癌治疗三期随机临床试验,其中92%由高收入国家主导,8%由低中收入国家主导。研究发现试验数量与全球疾病负担不匹配,低中收入国家试验更易达到主要终点且效应量更大,但存在资金和发表偏倚。

要点

  • 低中收入国家主导的肿瘤随机试验仅占8%,且试验规模更小、更少获得工业资助。
  • 低中收入国家试验更易达到主要终点(67% vs 45%),中位效应量更大(HR 0.62 vs 0.84)。
  • 低中收入国家试验发表于影响因子更低的期刊,负性结果试验的发表偏倚尤为明显。

核心结论

  • 肿瘤随机临床试验主要由高收入国家开展,且与全球癌症负担不匹配。
  • 低中收入国家试验更易发现有效疗法且效应量更大,但存在资金和发表偏倚。

研究设计与样本

  • 回顾性队列研究,通过文献检索纳入2014至2017年发表的694项评估抗癌治疗的三期随机临床试验。
  • 按世界银行经济分类将试验分为高收入国家主导(636项,92%)和低中收入国家主导(58项,8%)。

主要发现

  • 601项试验(87%)测试全身治疗,88项(13%)测试放疗或手术。
  • 乳腺癌试验占比高于其全球死亡占比(121项[17%] vs 7%死亡),而胃食管癌(38项[6%] vs 14%死亡)、肝癌(14项[2%] vs 8%死亡)、胰腺癌(14项[2%] vs 5%死亡)和宫颈癌(9项[1%] vs 3%死亡)试验占比低于死亡占比。
  • 高收入国家试验更可能由工业资助(464项[73%] vs 24项[41%],P < .001)。
  • 低中收入国家试验样本量更小(中位219例[IQR 137-363] vs 474例[IQR 262-743],P < .001),更易达到主要终点(39/58[67%] vs 286/636[45%],P = .001)。
  • 优越性试验中,低中收入国家观察到的中位效应量更大(风险比0.62[IQR 0.54-0.76] vs 0.84[IQR 0.67-0.97],P < .001)。

临床怎么用

  • 临床医生应认识到当前肿瘤随机试验证据主要来自高收入国家,低中收入国家试验证据有限。
  • 低中收入国家试验更易显示阳性结果且效应量更大,解读时需考虑试验规模小和潜在偏倚。
  • 政策制定者、研究资助者和期刊需采取措施解决资金和发表偏倚,加强低中收入国家随机试验能力建设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The burden of cancer falls disproportionally on low-middle-income countries (LMICs). It is not well known how novel therapies are tested in current clinical trials and the extent to which they match global disease burden. OBJECTIVES: To describe the design, results, and publication of oncology randomized clinical trials (RCTs) and examine the extent to which trials match global disease burden and how trial methods and results differ across economic settings. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study, a literature search identified all phase 3 RCTs evaluating anticancer therapies published from 2014 to 2017. Randomized clinical trials were classified based on World Bank economic classification. Descriptive statistics were used to compare RCT design and results from high-income countries (HICs) and low/middle-income countries (LMICs). Statistical analysis was conducted in January 2020. MAIN OUTCOMES AND MEASURES: Differences in the design, results, and output of RCTs between HICs and LMICs. RESULTS: The study cohort included 694 RCTs: 636 (92%) led by HICs and 58 (8%) led by LMICs. A total of 601 RCTs (87%) tested systemic therapy and 88 RCTs (13%) tested radiotherapy or surgery. The proportion of RCTs relative to global deaths was higher for breast cancer (121 RCTs [17%] and 7% of deaths) but lower for gastroesophageal cancer (38 RCTs [6%] and 14% of deaths), liver cancer (14 RCTs [2%] and 8% of deaths), pancreas cancer (14 RCTs [2%] and 5% of deaths), and cervical cancer (9 RCTs [1%] and 3% of deaths). Randomized clinical trials in HICs were more likely than those in LMICs to be funded by industry (464 [73%] vs 24 [41%]; P < .001). Studies in LMICs were smaller than those in HICs (median, 219 [interquartile range, 137-363] vs 474 [interquartile range, 262-743] participants; P < .001) and more likely to meet their primary end points (39 of 58 [67%] vs 286 of 636 [45%]; P = .001). The observed median effect size among superiority trials was larger in LMICs compared with HICs (hazard ratio, 0.62 [interquartile range, 0.54-0.76] vs 0.84 [interquartile range, 0.67-0.97]; P < .001). Studies from LMICs were published in journals with lower median impact factors than studies from HICs (7 [interquartile range, 4-21] vs 21 [interquartile range, 7-34]; P < .001). Publication bias persisted when adjusted for whether a trial was positive or negative (median impact factor: LMIC negative trial, 5 [interquartile range, 4-6] vs HIC negative trial, 18 [interquartile range, 6-26]; LMIC positive trial, 9 [interquartile range, 5-25] vs HIC positive trial, 25 [interquartile range, 10-48]; P < .001). CONCLUSIONS AND RELEVANCE: This study suggests that oncology RCTs are conducted predominantly by HICs and do not match the global burden of cancer. Randomized clinical trials from LMICs are more likely to identify effective therapies and have a larger effect size than RCTs from HICs. This study suggests that there is a funding and publication bias against RCTs led by LMICs. Policy makers, research funders, and journals need to address this issue with a range of measures including building capacity and capability in RCTs.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Wells JC, Sharma S, Del Paggio JC, et al. An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries. JAMA Oncol. 2021. PMID: 33507236. doi:10.1001/jamaoncol.2020.7478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。